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Abstract
Background: Tamoxifen is being used successfully to treat breast cancer. However, tamoxifen
also increases the risk of developing endometrial cancer in postmenopausal women. Raloxifene also
decreases breast cancer in women at high risk and may have a lower risk at developing cancer of
the uterus. Tamoxifen has been shown to stimulate arachidonic acid release from rat liver cells. I
have postulated that arachidonic acid release from cells may be associated with cancer
chemoprevention.
Methods: Rat liver, rat glial, human colon carcinoma and human breast carcinoma cells were
labelled with [3H] arachidonic acid. The release of the radiolabel from these cells during incubation
with tamoxifen and the raloxifene analog LY117018 was measured. The prostaglandin I2 produced
during incubation of the rat liver cells with µM concentrations of tamoxifen and the raloxifene
analog was quantitatively estimated.
Results: Tamoxifen is about 5 times more effective than LY117018 at releasing arachidonic acid
from all the cells tested. In rat liver cells only tamoxifen stimulates basal prostaglandin I2 production
and that induced by lactacystin and 12-O-tetradecanoyl-phorbol-13-acetate. LY117018, however,
blocks the tamoxifen stimulated prostaglandin production. The stimulated prostaglandin I2
production is rapid and not affected either by preincubation of the cells with actinomycin or by
incubation with the estrogen antagonist ICI-182,780.
Conclusions: Tamoxifen and the raloxifene analog, LY117018, may prevent estrogen-independent
as well as estrogen-dependent breast cancer by stimulating phospholipase activity and initiating
arachidonic acid release. The release of arachidonic acid and/or molecular reactions that
accompany that release may initiate pathways that prevent tumor growth. Oxygenation of the
intracellularly released arachidonic acid and its metabolic products may mediate some of the
pharmacological actions of tamoxifen and raloxifene.
Background
The successful treatment and prevention of estrogen-
dependent breast cancer in women by tamoxifen is attrib-
uted to its estrogen receptor (ER) occupancy [reviewed in
[1,2]]. In the N-nitrosomethylurea (NMU) induced breast
cancer model in rats, tumor growth is estrogen dependent
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and tamoxifen is considerably more effective than
raloxifene [3]. In the dimethylbenzanthracene (DMBA)-
induced model in rats, in which tumor growth is predom-
inantly dependent on prolactin for growth, tamoxifen and
raloxifene show effective anti-tumor action.
Tamoxifen and raloxifene have several properties in com-
mon; e.g. prevention of tumors in the DMBA induced rat
mammary model, maintenance of bone density in the
ovariectomized rat and reduction of low density lipopro-
tein cholesterol. The partial estrogen agonist activity of
tamoxifen on uterine tissue, however, increases the risk of
developing endometrial cancer. This does not appear to
occur with raloxifene.
Tamoxifen stimulates arachidonic acid release from rat
liver cells [4]. In this report, I have compared tamoxifen
and the raloxifene analog LY117018 for effectiveness at
releasing arachidonic acid (AA) from rat liver, rat glial,
human colon carcinoma and human breast carcinoma
cells and their effects on prostaglandin (PG) I2 production
by the rat liver cells. Although both compounds release
AA from these cells, LY117018 is less effective. Only
tamoxifen stimulates both basal and PGI2  production
induced by incubation of rat liver cells with lactacystin in
the presence of 12-O-tetradecanoyl-phorbol-13-acetate
(TPA). LY117018, however, inhibits the PGI2 production
stimulated by tamoxifen.
The intracellular release of AA and/or the cellular reac-
tions that accompany that release may initiate pathways
that prevent tumor growth. The tissue specific effects of
tamoxifen and LY117018 may be associated with the AA
or with cyclooxygenase (COX) activity and/or one of the
many bioactivities resulting from oxygenation and metab-
olism of the released AA.
Methods
The C-9 rat liver and BT-20 human breast carcinoma cells
were purchased from the American Type Culture Collec-
tion (Manassas, VA, USA) and maintained in MEM sup-
plemented with 10% fetal bovine serum. The C-6 rat glial
cell line was obtained from Dr. Elaine Y. Lai in the Depart-
ment of Biology, Brandeis University and maintained in
medium 199. The human colon carcinoma cells (HT-29)
were obtained from Dr. Basil Rigas, American Health
Foundation, Valhalla, NY and maintained in McCoy's
medium. [3H]AA (91.8 Ci/mmol) was purchased from
NEN Life Science Products, Inc. (Boston, MA, USA); ICI-
182,780 from Tocris Cookson, Inc. (Ballwin, MO, USA);
tamoxifen and 4-OH-tamoxifen were from Sigma Chemi-
cal Co. (St. Louis, MO, USA). LY117018 was obtained
from Dr. David A. Cox, Eli Lilly and Co. (Indianapolis, IN,
USA). Raloxifene was extracted from EVISTA® tablets with
dimethylsulfoxide.
Two days prior to experiments, the cells were treated with
0.25% trypsin-EDTA and, after addition of minimum
essential medium (MEM), medium 199 or McCoy's
medium containing 10% fetal bovine serum, the floating
cells were seeded onto 35 mm culture dishes. The plating
densities varied from 0.1 to 0.5 × 105 cells/35 mm dish.
The freshly seeded cultures were incubated for 24-h to
allow for cell attachment. After decantation of incubating
media, 1.0 ml fresh media (MEM for the rat liver and BT-
20 cells, medium 199 for the rat glial or McCoy's for the
HT-29 cells respectively) containing 10% fetal bovine
serum and [3H] AA (0.2 µCi/ml) was added and the cells
incubated for 24-h. The cells were washed 4 times with
MEM and incubated for various periods of time with 1.0
ml of MEM, medium 199 or McCoy's containing 1.0 mg
bovine serum albumin (BSA)/ml and different concentra-
tions of each test compound. The culture fluids were then
decanted, centrifuged at 2000 × g for 10 min, and 200 µl
of the supernate counted for radioactivity. Radioactivity
recovered in the washes before the 6-h incubation was
compared to input radioactivity to calculate the % radio-
activity incorporated into the cells [5].
As measured by thin layer chromatography (TLC), of the
[3H] released from radiolabelled methylcholanthrene
transformed fibroblasts (about 20% after a 3-h stimula-
tion by serum), 92% was AA, 4% was PGE2, 0.6% and 1%
were PGF2α and phospholipids respectively [6]. When
labelled to equilibrium, the [3H] AA had been incorpo-
rated into phosphatidylcholine (50%), phosphatidyleth-
anolamine (36%), phodphatidylserine (9%) and
triglycerides (10%) [7]. Such distribution varied among
12 cell lines [8]. The [3H] AA label released from human
colorectal cancer cell lines (HCT116 and SW180) was AA
as measured by TLC [9].
For PGI2 production by the rat liver cells, 1.0 ml of MEM
supplemented with 10% fetal bovine serum, lacking [3H]
AA, was added after the first 24-h incubation. The cells
were incubated for another 24-h, washed three times with
MEM, then incubated with lactacystin and TPA in the
presence and absence of the test compounds in MEM/BSA
for various periods of time. The culture fluids were
decanted and analyzed for 6-keto-PGF1α, the stable hydro-
lytic product of PGI2, by radioimmunoassay [10]. At the
sub-confluent cell densities used in these experiments
(about 5 × 104 or less per dish) only the major COX prod-
uct of rat liver cells (97% 6-keto-PGF1α) could be meas-
ured. The other two COX products, PGE2 (2%) and PGF2α
(1%) could not be measured.
The release of [3 H] AA is presented as a percentage of the
radioactivity incorporated by the cells. Except for the time-
course experiments, which used duplicate dishes (Fig. 5),
three to six culture dishes were used for each experimentalBMC Cancer 2004, 4:49 http://www.biomedcentral.com/1471-2407/4/49
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point. The data are expressed as mean values ± SEM. The
data were evaluated statistically by the unpaired Student's
t-test. A P value < 0.05 was considered significant.
Results
AA Release
The release of AA after incubation of the rat liver cells with
tamoxifen, 4-OH-tamoxifen, LY117018 and raloxifene for
6 h is shown in Fig. 1-A. Tamoxifen is the most effective:
it releases AA at 10 µM. 4-OH-tamoxifen, an active metab-
olite of tamoxifen [2] is also effective. Raloxifene and
LY117018 release AA from the rat liver cells, but are about
5 times less potent (at the doses tested) than tamoxifen. At
µM concentrations, all induce apoptosis [11,12].
Tamoxifen, but not 4-OH-tamoxifen, has also been
reported to induce apoptosis in p53(-) normal human
mammary epithelial cells [13]. Yet, the metabolite binds
to the ER with higher affinity than tamoxifen [14,15]. The
release of AA by tamoxifen and LY117018 is not unique to
the rat liver cells. Both release AA from rat glial cells (Fig.
1-B). Tamoxifen is more effective at releasing AA than is
LY117018.
The highest level of [3H] AA released into the medium
which contains BSA (1 mg/ml) would be 0.25 nM (the
specific activity of the [3H] AA is 92 Ci/mmole). Since TLC
or HPLC analyses were not done, the concentration of the
total released AA could not be quantitatively estimated.
However, even treatment of a colorectal cancer cell line
with 200 µM AA for 48-h leads to apoptosis [9].
The release of AA is neither species nor tissue specific.
Both drugs also release AA from human breast carcinoma
(BT-20) and human colon carcinoma (HT-29) cells (Fig.
2-A and 2-B). Again, LY117018 is less effective than
tamoxifen.
PGI2 production
Of the cultured cells studied, the COX mediated meta-
bolic profile of AA has been described only in the rat liver
cells. Thus, the effects of tamoxifen and LY117018 on
PGI2  production by these cells were determined.
Tamoxifen stimulates basal PGI2 production as well as
that induced by lactacystin in the presence of TPA.
LY117018 and raloxifene (Fig. 3-A) are ineffective in stim-
ulating basal PGI2 production. LY117018, at a concentra-
tion that does not affect PGI2  production (50 µM),
inhibits the PGI2 production stimulated by lactacystin in
the presence of TPA (Fig. 3-B). The increased PGI2 produc-
tion probably reflects some stimulation of both induced
and basal COX activity. In mouse neuronal and embry-
onic rat mesencephalic cells, COX-2 is induced by lacta-
cystin as measured by western and northern blot analyses
[16].
Identification of the induced and basal isoforms stimu-
lated by tamoxifen in these rat liver cells was deduced
AA release from (A) rat liver cells (C-9) stimulated by  tamoxifen, 4-OH-hydroxy-tamoxifen, LY117018 and  raloxifene and (B) from rat glial cells incubated with  tamoxifen and LY117018 Figure 1
AA release from (A) rat liver cells (C-9) stimulated by 
tamoxifen, 4-OH-hydroxy-tamoxifen, LY117018 and 
raloxifene and (B) from rat glial cells incubated with 
tamoxifen and LY117018. The cells were incubated for 6-h. 
The analyses were performed with triplicate dishes. Each bar 
gives the mean value and the brackets give the SEM. * = sta-
tistically significant vs control. The data are representative of 
several independent experiments with similar results.
AA release from (A) human breast carcinoma cells (BT-20)  and (B) human colon carcinoma cells (HT-29) by tamoxifen  and LY117,018 Figure 2
AA release from (A) human breast carcinoma cells (BT-20) 
and (B) human colon carcinoma cells (HT-29) by tamoxifen 
and LY117,018. The cells were incubated for 6-h. The analy-
ses were performed with triplicate dishes. Each bar gives the 
mean values and the brackets give the SEM. * = statistically 
significant vs appropriate MEM/BSA control. The data are 
representative of several independent experiments.BMC Cancer 2004, 4:49 http://www.biomedcentral.com/1471-2407/4/49
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from the relative effectiveness of inhibition of PGI2 pro-
duction by celecoxib and piroxicam. Celecoxib is 7.5
times more effective than piroxicam as an inhibitor of
COX-2, but 30,000 times less effective as an inhibitor of
COX-1. Piroxicam is a selective inhibitor of COX-1 [17].
Celecoxib, the nonsteroidal anti-inflammatory drug
(NSAID) that is a selective inhibitor of COX-2, inhibits
both induced and basal COX activity 20–80 times more
effectively than piroxicam (Fig. 4-A and 4B). Thus, based
on inhibition by these two NSAIDs, COX-2 is the most
likely isoform expressed both constitutively and after
induction by lactacystin in the presence of TPA in rat liver
cells. This conclusion was confirmed by western blot anal-
yses (Levine L, Tashjian A, unpublished data).
Is COX-2 production non-genomic and ER-independent?
The time-course of stimulation by tamoxifen (15 µM) of
basal activity is shown in Fig. 5. Even after a 5-minute
incubation (not shown in Fig. 5), stimulation by
tamoxifen is significant statistically [0.08 ± 0.011 (n = 5)
vs 0.13 ± 0.011 (n = 5) ng 6-keto-PGF1α per ml in the
absence and presence of tamoxifen, respectively]. Similar
to AA release [4], stimulation of basal PGI2 production by
tamoxifen is not affected by preincubation of the cells for
2-h with 1 µM actinomycin D. The induction obtained by
incubation with lactacystin in the presence of TPA is
inhibited (Fig. 6-A). Stimulation of basal PGI2 production
by tamoxifen is unaffected by ICI-182,780 (Fig. 6-B). This
estrogen antagonist, which binds to the ER with high
affinity [18] did not affect the release of AA by tamoxifen
[4] but does partially inhibit release of AA stimulated by
17β-estradiol, 22 (R)-cholesterol, indomethacin, trans-
Effect of tamoxifen, LY117018 or raloxifene on (A) basal 6- keto-PGF1α production and (B) the effect of tamoxifen or  LY117018 on 6-keto-PGF1α production induced by lactacys- tin in the presence of TPA Figure 3
Effect of tamoxifen, LY117018 or raloxifene on (A) basal 6-
keto-PGF1α production and (B) the effect of tamoxifen or 
LY117018 on 6-keto-PGF1α production induced by lactacys-
tin in the presence of TPA. Rat liver cells were incubated for 
6-h. The analyses were performed with triplicate or quadru-
plicate dishes. Each bar gives the mean value and the brackets 
the SEM. * = Statistically significant vs control stimulation. ** 
= Statistically significant vs lactacystin plus TPA control. The 
data are representative of several independent experiments 
with the same results.
Inhibition of (A) tamoxifen (16 µM)-stimulated basal and (B)  tamoxifen-stimulated induced 6-keto-PGF1α production (lac- tacystin in the presence of TPA) by celecoxib (*) and piroxi- cam () Figure 4
Inhibition of (A) tamoxifen (16 µM)-stimulated basal and (B) 
tamoxifen-stimulated induced 6-keto-PGF1α production (lac-
tacystin in the presence of TPA) by celecoxib (*) and piroxi-
cam (). Rat liver cells were incubated with either (A) 
tamoxifen (16 µM) or (B) lactacystin plus TPA in the pres-
ence of tamoxifen, for 6-h. The analyses were performed 
with triplicate dishes.BMC Cancer 2004, 4:49 http://www.biomedcentral.com/1471-2407/4/49
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retinoic acid and the tyrosine analog of thiazolidinedione,
GW7845 [19]. The rapidity of stimulation (5 min) and
the lack of effect of actinomycin D or ICI-182,780 suggest
that the stimulation of PGI2 production by tamoxifen is
non-genomic and does not require ER occupancy.
LY117018 blocks PGI2  production stimulated by
tamoxifen (Fig. 7). This blockade is unaffected by preincu-
bation of the cells for 2-h with either actinomycin D or
ICI-182,780 (data not shown). LY117018, however, does
not inhibit the release of AA stimulated by tamoxifen;
their combined effect is at least additive (Fig. 8).
Discussion
These studies demonstrate that, at µM concentrations,
tamoxifen and the raloxifene analog, LY117,018 stimulate
the release of AA from cells in culture. At nM levels, the
release is not observed. The effectiveness of these two
compounds at prevention of estrogen-dependent breast
cancer reflects competition for the ER [1,2]. In addition to
occupancy of the ER, I am postulating that these drugs, at
µM concentrations, may also prevent breast cancer of
estrogen independent tumors. Consistent with this
hypothesis are the findings that even at 100 µM concen-
trations, ethanol extracts of Femora ® (letrozole) or Arami-
dex ® (anastrozole) do not release AA from cells in culture
(unpublished data). These two drugs inhibit estrogen syn-
thesis by blocking aromatase enzymes and also prevent
estrogen-dependent breast cancer [20]. In view of the
stimulations of AA release by tamoxifen and LY117018
from human colon carcinoma cells (Fig. 2-A), the occur-
rence of colon cancer in women undergoing long term
treatment with high levels of tamoxifen would be of
interest.
A mechanism that most simply explains the release of AA
by tamoxifen and LY117018 is the ability of such com-
pounds to intercalate into cell membranes and affect
phospholipase activities. The release of AA from endothe-
lial cells by the Ca2+ ionophore A-23187 reflects phos-
pholipase activities. It is regulated by phosphorylation of
the enzyme [21]. The enzymic properties of the altered
membrane may impact signaling mechanisms e.g.,
Time-course of 6-keto-PGF1α production by rat liver cells  during incubation with 15 µM tamoxifen (γ) and MEM/BSA  control (O) Figure 5
Time-course of 6-keto-PGF1α production by rat liver cells 
during incubation with 15 µM tamoxifen (γ) and MEM/BSA 
control (O). Analyses were performed with duplicate and 
triplicate dishes; mean values are shown.
Effect of (A) actinomycin D on basal or induced (lactacystin  plus TPA) 6-keto-PGF1α production stimulated by tamoxifen  and (B) effect of ICI-182,780 on basal 6-keto-PGF1α produc- tion stimulated by tamoxifen Figure 6
Effect of (A) actinomycin D on basal or induced (lactacystin 
plus TPA) 6-keto-PGF1α production stimulated by tamoxifen 
and (B) effect of ICI-182,780 on basal 6-keto-PGF1α produc-
tion stimulated by tamoxifen. In (A), rat liver cells were pre-
incubated with 1 µM actinomycin for 2-h and then incubated 
with tamoxifen (16 µM) or lactacystin plus TPA for 6-h. In 
(B), rat liver cells were incubated with tamoxifen (16 µM) 
and tamoxifen in the presence and absence of ICI-182,780 
(16 µM) for 6-h. The analyses were performed with triplicate 
dishes. Each bar gives the mean value and the brackets give 
the SEM. Parts of the experiments were repeated several 
times with the same results. * Statistically significant vs con-
trol. ** Statistically significant vs lactacystin plus TPA.BMC Cancer 2004, 4:49 http://www.biomedcentral.com/1471-2407/4/49
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pathways leading to apoptosis and COX induction. The
intracellularly released AA also can serve as substrate for
oxygenases. AA has intrinsic biologic activities that may
also affect signaling pathways. Such changes would
depend on the lipophilic properties of the compound and
the composition of a particular membrane [22] and
would vary from cell type to cell type, organelle to
organelle and with the growth phase of the cell.
The AA release by tamoxifen and other reagents studied in
my laboratory occurs with µM concentrations
[4,5,19,23,24]. These experiments were carried out in the
presence of BSA (1.0 mg/ml), and therefore do not differ-
entiate between the protein-bound and free reagent. Thus,
they are likely to be overestimated values. Nevertheless,
the possibility that general necrotic cell death may cause
AA release, must be considered. Tamoxifen, was found not
to be toxic at concentrations of 10 to 20 µM for A549
human lung adenocarcinoma (ER-negative) cells [25].
Nor was 10 µM tamoxifen toxic when tested on rat glial
cells and breast cancer MCF-7 cells [26]. Even when cell
viability of three different breast cell lines (ER-positive
MCF-7; ER-negative MDA-MB-239 and ER-negative BT-20
cells) was measured after incubation with 25 µM
tamoxifen for 24-h, the loss in viability was due to
apoptosis [12] and was not the result of necrotic cell
death. Concentrations of tamoxifen used in this report are
comparable to those found to induce apoptosis, not
necrotic cell death. The median concentration of
tamoxifen and its metabolites for clinical effectiveness in
the treatment of breast cancer varies from 0.8 µM to 2.4
µM, depending on the age of the woman [27].
When measured after a 6-h incubation, 10 µM tamoxifen
stimulates deesterification of membrane phospholipids as
measured by extracellular AA release, (Fig. 1 and 2). The
6-h incubation may not be optimum for apoptosis to be
observed, e.g. after a 6-h incubation of 5 µM tamoxifen
with breast cancer cells, apoptosis was induced in about
10% of the cells compared to 8% in control cells [12].
After 24- and 48-h incubation, apoptosis in the tamoxifen
treated cells increased to 40 and 70%, respectively.
Apoptosis, induced by this membrane perturbation after
6-h incubation, increased 4 to 7 fold after longer
Effect of tamoxifen, LY117018 and tamoxifen plus LY118018  (all at 16 µM), on 6-keto-PGF1α production Figure 7
Effect of tamoxifen, LY117018 and tamoxifen plus LY118018 
(all at 16 µM), on 6-keto-PGF1α production. The rat liver 
cells were incubated 6-h. The analyses were performed with 
quintuplicate dishes. Each bar gives the mean value and the 
brackets the SEM. * Statistically significant vs tamoxifen.
AA release from rat liver cells by tamoxifen (12 µM),  LY117018 (48 µM) and tamoxifen in presence of LY117018 Figure 8
AA release from rat liver cells by tamoxifen (12 µM), 
LY117018 (48 µM) and tamoxifen in presence of LY117018. 
Cells were incubated for 6-h. The analyses were performed 
with triplicate dishes. Each bar gives the mean value and the 
brackets the SEM. * = Statistically significant vs MEM/BSA 
control. ** = Statistically significant vs tamoxifen.BMC Cancer 2004, 4:49 http://www.biomedcentral.com/1471-2407/4/49
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incubation. It is apoptosis that may mediate the cancer
preventative action of tamoxifen [11,12].
Some tissue specific effects of tamoxifen and raloxifene,
e.g. on endometrial cells of the uterus, may be related to
COX activity. At the low cell densities used in the present
studies, the PGI2 produced by the rat liver cells can be
quantitatively determined. The effects of tamoxifen and
LY117018 on the COX activity of the rat liver cells may be
similar to their effects on other cells that express COX.
Tamoxifen and LY117018 affect COX activity differently;
only tamoxifen stimulates PGI2 production. AA, which
regulates the production of lipoxygenase, COX and
cytochrome P-450 epoxygenase products could impact
many of the pharmacological actions of these two selec-
tive estrogen receptor modulators. AA can be oxygenated
by COX isoforms, lipoxygenases, and cytochrome P-450
epoxygenases and their products converted to the prostag-
landins, leukotrienes, epoxyeicostetranoic acids [28] and
AA to the oxidative stress-related isoprostanes [29]. In the
COX pathway, enzymes convert PGH2 to the major phys-
iologically active products, PGD2, PGE2, PGF2α, PGI2 and
thromboxane A2 [28]. They, in turn, can be converted
enzymatically and nonenzymatically to other biologically
active compounds that possess different pharmacological
properties. Often, only one major product is synthesized
by the cell [8]. Thus, tissues can be affected differently by
changes in COX activity. AA or its metabolites, would
have different biological effects depending upon the
genetic capabilities of the individual cell being affected. In
addition to the spectrum of activities of the prostanoids,
oxygenation of AA by 5-, 12- and 15-lipoxygenase and
epoxygenases yield other products located in different
cells and tissues [30,31].
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